Published February 17, 2021, 9:32 AM
People may be wondering what is the difference between the vaccine clinical trials, which involved the Task Group on Vaccine Evaluation and Selection (TG-VES) of the Department of Science and Technology (DOST) and the actual vaccination program that is set to be implemented by the Duterte government within this month.
(Photo by Robyn Beck / AFP / FILE PHOTO / MANILA BULLETIN)
Department of Science and Technology Secretary Fortunato T. de la Peña is gracious enough to walk us through how clinical trials are being conducted.
“‘Yung clinical trials na involved ang DOST through the Task Group on Vaccine Evaluation and Selection ay part pa ng process bago makabuild ng sufficient basis to determine its safety and efficacy (The clinical trials involving the DOST through the Task Group on Vaccine Evaluation and Selection are still part of the process before building a sufficient basis to determine its safety and efficacy),” he told th
Department of Science and Technology Secretary Fortunato dela Peña
(TOTO LOZANO / Presidential Photo / MANILA BULLETIN FILE PHOTO)
DOST Secretary Fortunato T. de la Peña said both parties made such commitment during the first Philippines-France Joint Committee Meeting held on Feb. 5.
“The meeting discussed updates on existing initiatives and identified priorities and specifics for future collaborations, guided by the signed Program of Cooperation,” he said in his weekly report.
He noted that DOST Undersecretary Rowena Cristina L. Guevara and her co-Chair, MESRI Dr. Denis Despréaux, “led the Committee to agree on the way forward” for the continued implementation of the Hubert Curien Partnership-Science for the People Researchers Mobility Program and the DOST-PhilFrance Scholarship Program.
Published February 4, 2021, 2:12 PM
The areas with high incidence of coronavirus disease-2019 (COVID-19) are to be prioritized in the clinical trials of vaccines developers that have been been approved to conduct their Phase 3 clinical trials in the Philippines, according to Department of Science and Technology (DOST) Secretary Fortunato dela Peña.
Department of Science and Technology Secretary Fortunato dela Peña (TOTO LOZANO/ Presidential Photo / MANILA BULLETIN FILE PHOTO)
During the televised “Laging Handa” briefing, he said the clinical trials in COVID-19 risk areas will be conducted for “one month or less”.
“Required na ang pagdadausan ng clinical trials at ito naman ay hindi magtatagal siguro ng isang buwan or even less, ay gagawin sa mga lugar na mataas ang incidence ng COVID-19 at kailangan ay mataas na incidence na yun ay consisitent over the last the last two weeks bago magumpisa ang clinical trials (It is required that the clinical trials, which may last f
Department of Science and Technology Secretary Fortunato dela Peña
(TOTO LOZANO / Presidential Photo / MANILA BULLETIN FILE PHOTO)
“Kung meron pong hindi magandang epekto ‘yung trial vaccines dun sa pasyente, yan po ay sagot ng vaccine company (If the trial vaccines have adverse effects on the patient, the vaccine company will be held responsible),” he said during a televised briefing.
The DOST Chief said the local government units (LGUs) will not spend a single centavo for the conduct of clinical trials by the vaccine developers that were given green light to conduct their Phase 3 clinical trial in the Philippines.
This week, the Belgium-based Janssen Pharmaceuticals will start its coronavirus vaccine clinical trials.
endIndex:
Metro Manila (CNN Philippines, January 29) Twelve more vaccine developers have signed confidentiality deals with the government for their COVID-19 clinical trial application, Department of Science and Technology Secretary Fortunato dela Peña said on Friday.
During a virtual briefing, the official reiterated that 25 vaccine makers were in negotiations with the government to possibly run clinical trials in the Philippines. Out of these, there are already 12 that have signed confidentiality disclosure agreement, he said. Similar CDAs were signed earlier with three other vaccine makers whose clinical trials have been approved, bringing the total number of such agreement to 15.
Dela Peña said a company which has secured a CDA with the government is required to submit its data for further evaluation by the country s vaccine expert panel and the health research ethics board.